Bertrand OF, et al. - In order to gain clarity regarding the risk/benefit ratio of glycoprotein IIb/IIIa inhibitors with dual oral antiplatelet therapy after failed thrombolysis and rescue percutaneous coronary intervention (PCI), researchers compared intravenous (IV) and intracoronary (IC) abciximab delivery in patients referred for rescue transradial PCI. They looked for primary angiographic endpoints (final Thrombolysis in Myocardial Infarction [TIMI] flow and myocardial blush grades) and secondary endpoints (acute and 6-month outcomes using angiographic parameters, platelet aggregation parameters, cardiac biomarkers, cardiac magnetic resonance measurements [CMR]) and clinical endpoints. Overall, no significant clinical impact of IC or IV abciximab was seen, compared with placebo, in STEMI patients presenting with failed thrombolysis undergoing transradial rescue PCI.